Equibles does not estimate personal net worth.
Get an email with a short summary when Assembly Biosciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get ASMB alertsJason A. Okazaki is recorded as Board Member at Assembly Biosciences, Inc. (ASMB) since June 4, 2026, COO at Assembly Biosciences, Inc. (ASMB) since August 1, 2022 and CEO at Assembly Biosciences, Inc. (ASMB). The newest filing on record that lists Jason A. Okazaki as CEO at Assembly Biosciences, Inc. (ASMB) is dated April 22, 2026. Assembly Biosciences, Inc. reported in an 8-K filed June 5, 2026 that Jason A. Okazaki was appointed Director, effective June 4, 2026. Assembly Biosciences, Inc. reported in an 8-K filed June 3, 2024 that Jason A. Okazaki was appointed Director, effective May 29, 2024. Assembly Biosciences, Inc. reported in an 8-K filed May 30, 2023 that Jason A. Okazaki was appointed Director, effective May 25, 2023. Equibles holds 7 filed executive changes naming Jason A. Okazaki; each is listed under recent activity with its source filing. The proxy statement of Assembly Biosciences, Inc. reports total compensation of $2,482,987 for Jason A. Okazaki in fiscal 2025, including a base salary of $647,500. Disclosed compensation is on record for 6 fiscal years. Jason A. Okazaki has spoken on 2 investor events across 1 company, most recently for Assembly Biosciences, Inc. on June 8, 2026. Assembly Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Assembly Biosciences, Inc. includes John G. McHutchison, A.O., M.D. (Chairman and Board Member), Jeanette M. Bjorkquist (CFO), Michael P. Samar (CFO and Chief Accounting Officer) and 7 others.
“The stockholders elected of the following to serve on the Company's Board of Directors until the Company's 2027 annual meeting of stockholders and until their successors are duly elected and qualified: Anthony E. Altig; Tomas Cihlar, Ph.D.; Gina Consylman; Robert D. Cook II; Sir Michael Houghton, Ph.D.; Lisa R. Johnson-Pratt, M.D.; Susan Mahony, Ph.D.; John G. McHutchison, A.O., M.D.; and Jason A. Okazaki.”
“William R. Ringo, Jr., Anthony E. Altig, Tomas Cihlar, Ph.D., Gina Consylman, Robert D. Cook II, Sir Michael Houghton, Ph.D., Lisa R. Johnson-Pratt, M.D., Susan Mahony, Ph.D., John G. McHutchison, A.O., M.D. and Jason A. Okazaki were each elected to serve on the Company's Board of Directors until the Company's 2025 annual meeting of stockholders and until their successors are duly elected and qualified.”
“Yeah, so basically Assembly Bioscience is a small biotech company located in South San Francisco. Our focuses today are primarily HSV-2, recurrent general herpes, as well as hepatitis delta.”
“So I think, as you might recall, last year was a pretty big year for us from an ASV standpoint. So our two flagship molecules, 5366 and 1179, both demonstrated high proof-of-concept data in the phase 1B studies.”
2026-06-04–present
2022-08-01–present
Start not stated–present
Last confirmed April 22, 2026
Biotechnology · Healthcare
CEO, Board Member, COO
2022-08-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Assembly Biosciences, Inc. (ASMB) | Chief Executive Officer and President | $647,500 | $2,482,987 |
| 2024 | Assembly Biosciences, Inc. (ASMB) | Chief Executive Officer and President | $626,250 | $1,767,191 |
| 2023 | Assembly Biosciences, Inc. (ASMB) | Chief Executive Officer and President | $600,000 | $1,373,710 |
| 2022 | Assembly Biosciences, Inc. (ASMB) | Chief Executive Officer and President | $554,583 | $1,801,214 |
| 2021 | Assembly Biosciences, Inc. (ASMB) | Chief Operating Officer | $532,521 | $1,278,822 |
| 2020 | Assembly Biosciences, Inc. (ASMB) | Chief Operating Officer | $394,173 | $3,905,018 |
